Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $231

Benzinga · 2d ago
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $210 to $231.